Understanding recent clinical failures (e.g., IDO-1 antagonists) and the lack of correlation between PD-L1 expression and response to anti-PD-L1 highlight the need to define where particular drugs principally act—within the tumor or in a lymphoid organ/organoid. Here, IDO1 is linked to neoplasm.